Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity

References

• Ahren B, Carr RD, Deacon CF. (2010). Incretin hormone secretion over the day. Vitam. Horm, 84:203–20
   PubMed Web of Science ®Google Scholar
• Ali S, Lamont BJ, Charron MJ, Drucker DJ. (2011). Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest, 121:1917–29
   PubMed Web of Science ®Google Scholar
• Amland PE, Jorde R, Burthol PG, Giercksky KE. (1985). Effect of intravenously infused porcine GIP on serum insulin in obese and lean subjects studied with the hyperglycemic clamp technique. Scand J Gastroenterol, 20:309–14
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. (2007). Biology of incretins, GLP- 1 and GIP. Gastroenterology, 132:2131–57
   PubMed Web of Science ®Google Scholar
• Bailey SJ, Ravier MA, Rutter GA. (2007). Glucose-dependent regulation of gamma-aminobutyruc acid (GABA A) receptor expression in mouse pancreaytic islet alpha-cells. Diabetes, 56:320–27
   PubMed Web of Science ®Google Scholar
• Bando Y, Aoki H, Hisada K, et al. (2012). Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 Diabetic patients. J Diabetes Investig, 3:170–4
   PubMed Web of Science ®Google Scholar
• Bollag RJ, Zhong Q, Phillips P, et al. (2000). Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology, 141:1228–35
   PubMed Web of Science ®Google Scholar
• Brubaker PL. (2006). The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann NY Acad Sci, 1070:10–26
   PubMed Web of Science ®Google Scholar
• Carr RD, Larsen MO, Jelic K, et al. (2010). Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab, 95:872–8
   PubMed Web of Science ®Google Scholar
• Cunha DA, Ladrière L, Ortis F, et al. (2009). Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes, 58:2851–62
   PubMed Web of Science ®Google Scholar
• Cuthbertson J, Patterson S, O’Harte FP, Bell PM. (2011). Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism, 60:52–6
   PubMed Web of Science ®Google Scholar
• Dao TM, Waget A, Klopp P, et al. (2011). Resveratrol increases glucose induced GLP-1 secretion in mice, a mechanism which contributes to the glycemic control. PLoS One [Online] Available from: http//www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0020700. [last accessed on 6 Jun 2011]
   Google Scholar
• de Heer J, Rasmussen C, Coy DH, Holst JJ. (2008). Glucagon- like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia, 51:2263–70
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. (1995b). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 80:952–57
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Meier J, et al. (2000). Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab, 85:3575–81
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. (1995a). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 44:1126–31
   PubMed Web of Science ®Google Scholar
• Deacon CF, Pridal L, Klarskov L, et al. (1996). Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol, 271:E458–64
   PubMed Web of Science ®Google Scholar
• Deacon CF. (2005). What do we know about the secretion and degradation of incretin hormones? Regul Pept, 128:117–24
   PubMed Web of Science ®Google Scholar
• Deane AM, Nguyen NQ, Stevens JE, et al. (2010). Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab, 95:215–21
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Philippe J, Mojsov S, et al. (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA, 84:3434–8
   PubMed Web of Science ®Google Scholar
• Ebert R, Creutzfeldt W. (1992). Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia. Acta Diabetol Lat, 26:1–15
   Google Scholar
• Edwards CM, Todd JF, Mahmoudi M, et al. (1999). Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans, studies with the antagonist exendin 9–39. Diabetes, 48:86–93
   PubMed Web of Science ®Google Scholar
• Eissele R, Göke R, Willemer S, et al. (1992). Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest, 22:283–91
   PubMed Web of Science ®Google Scholar
• Ellingsgaard H, Hauselmann I, Schuler B, et al. (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med, 17:1481–9
   PubMed Web of Science ®Google Scholar
• Elliott RM, Morgan LM, Tredger JA, et al. (1993). Glucagon-like peptide-1 (7–36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man, acute post-prandial and 24-h secretion patterns. J Endocrinol, 138:159–66
   PubMed Web of Science ®Google Scholar
• Elrick H, Stimmer L, Hlad Jr CJ, Arai Y. (1964). Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab, 24:1076–82
   PubMed Web of Science ®Google Scholar
• Fehmann HC, Habener JF. (1992). Insulinotropic hormone glucagon-like peptide-I (7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology, 130:159–66
   PubMed Web of Science ®Google Scholar
• Franklin J, Gromada J, Glinovci A, et al. (2005). Beta-cell secretory products activate alphacell ATP-dependent potassium channels to inhibit glucagon release. Diabetes, 54:1808–15
   PubMed Web of Science ®Google Scholar
• Fujita Y, Wideman RD, Asadi A, et al. (2010). Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology, 138:1966–75
   PubMed Web of Science ®Google Scholar
• Green B, Duffy NA, Irwin N, et al. (2006). Inhibition of dipeptidyl peptidase IV (DPPIV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide–1 (GLP-1). Eur J Pharmacol, 547:192–9
   PubMed Web of Science ®Google Scholar
• Guzzardi MA, Iozzo P. (2011). Fatty heart, cardiac damage, and inflammation. Rev Diabet Stud, 8:403–17
   PubMedGoogle Scholar
• Hansen KB, Vilsbøll T, Bagger JI, et al. (2010). Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab, 95:3309–17
   PubMed Web of Science ®Google Scholar
• Hansotia T, Baggio LL, Delmeire D, et al. (2004). Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes, 53:1326–35
   PubMed Web of Science ®Google Scholar
• Hare KJ, Vilsbøll T, Asmar M, et al. (2010). The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose lowering action. Diabetes, 59:1765–70
   PubMed Web of Science ®Google Scholar
• Hayes MR, Bradley L, Grill HJ. (2009). Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology, 150:2654–9
   PubMed Web of Science ®Google Scholar
• Heller RS, Aponte GW. (1995). Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Am J Physiol, 269:G852–60
   PubMed Web of Science ®Google Scholar
• Heller RS, Kieffer TJ, Habener JF. (1997). Insulinotropic glucagon like peptide I receptor expression in glucagon producing alpha cells of the rat endocrine pancreas. Diabetes, 46:785–91
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Bjarnason NH, et al. (2003). Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res, 18:2180–9
   PubMed Web of Science ®Google Scholar
• Hojberg PV, Vilsbøll T, Rabøl R, et al. (2009). Four weeks of near normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia, 52:199–207
   PubMed Web of Science ®Google Scholar
• Holst JJ, Burcelin R, Nathanson E. (2011). Neuroprotective properties of GLP-1, theoretical and practical applications. Curr Med Res Opin, 27:547–58
   PubMed Web of Science ®Google Scholar
• Holst JJ, Orskov C, Nielsen OV, Schwartz TW. (1987). Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett, 211:169–74
   PubMed Web of Science ®Google Scholar
• Holst JJ. (2007). The physiology of glucagon-like peptide 1. Physiol Rev, 87:1409–39
   PubMed Web of Science ®Google Scholar
• Jin HY, Liu WJ, Park JH, et al. (2009). Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res, 40:536–44
   PubMed Web of Science ®Google Scholar
• Jolivalt CG, Fineman M, Deacon CF, et al. (2011). GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab, 13:990–1000
   PubMed Web of Science ®Google Scholar
• Kappe C, Patrone C, Holst JJ, et al. (2013). Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol, 8:322–32
   Google Scholar
• Kawashima S, Matsuoka TA, Kaneto H, et al. (2011). Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. Biochem Biophys Res Commun, 404:534–40
   PubMed Web of Science ®Google Scholar
• Kjems LL, Holst JJ, Vølund A, Madsbad S. (2003). The influence of GLP-1 on glucose-stimulated insulin secretion, effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes, 52:380–86
   PubMed Web of Science ®Google Scholar
• Knop FK, Aaboe K, Vilsbøll T, et al. (2012). Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab, 14:500–10
   PubMed Web of Science ®Google Scholar
• Knop FK, Vilsbøll T, Højberg PV, et al. (2007). Reduced incretin effect in type 2 diabetes, cause or consequence of the diabetic state? Diabetes, 56:1951–9
   PubMed Web of Science ®Google Scholar
• Krarup T. (1988). Immunoreactive gastric inhibitory polypeptide. Endocr Rev, 9:122–34
   PubMed Web of Science ®Google Scholar
• Kreymann B, Williams G, Ghatei MA, Bloom SR. (1987). Glucagon-like peptide-1 7-36, a physiological incretin in man. Lancet, 2:1300–304
   PubMed Web of Science ®Google Scholar
• Laviola L, Leonardini A, Melchiorre M, et al. (2012). Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology, 153:5770–81
   PubMed Web of Science ®Google Scholar
• Lehrke M, Marx N. (2011). Cardiovascular effects of incretin based therapies. Rev Diabet Stud, 8:382–91
   PubMedGoogle Scholar
• Lindsay JR, Duffy NA, McKillop AM, et al. (2005). Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med, 22:654–7
   PubMed Web of Science ®Google Scholar
• Liu WJ, Jin HY, Lee KA, et al. (2011). Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol, 164:1410–20
   PubMed Web of Science ®Google Scholar
• Lu SS, Yu YL, Zhu HJ, et al. (2009). Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol, 200:159–65
   PubMed Web of Science ®Google Scholar
• Madsbad S, Krarup T, Deacon CF, Holst JJ. (2008). Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes, a review of clinical trials. Curr Opin Clin Nutr Metab Care, 11:491–9
   PubMed Web of Science ®Google Scholar
• Maida A, Lamont BJ, Cao X, Drucker DJ. (2011). Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-a in mice. Diabetologia, 54:339–49
   PubMed Web of Science ®Google Scholar
• Marchetti P, Lupi R, Bugliani M, et al. (2012). A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia, 55:3262–72
   PubMed Web of Science ®Google Scholar
• Martin JH, Deacon CF, Gorrell MD, Prins JB. (2011). Incretin-based therapies, review of the physiology, pharmacology and emerging clinical experience. Intern Med J, 41:299–307
   PubMed Web of Science ®Google Scholar
• Mayo KE, Miller LJ, Bataille D, et al. (2003). International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev, 55:167–94
   PubMed Web of Science ®Google Scholar
• McIntyre N, Holdsworth CD, Turner DS. (1964). New interpretation of oral glucose tolerance. Lancet, 2:20–1
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Askenas M, et al. (2005). Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia, 48:1872–81
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Siepmann N, et al. (2003). Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia, 46:798–801
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. (2010). Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired function? Diabetes, 59:1117–25
   PubMed Web of Science ®Google Scholar
• Migoya EM, Bergeron R, Miller JL, et al. (2010). Dipeptidyl-peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther, 88:801–8
   PubMed Web of Science ®Google Scholar
• Miyawaki K, Yamada Y, Yano H, et al. (1999). Glucose intolerance caused by a defect in the entero-insular axis, a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA, 96:14843–7
   PubMed Web of Science ®Google Scholar
• Miyawaki K, Yamada Y, Ban N, et al. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med, 8:738–42
   PubMed Web of Science ®Google Scholar
• Moens K, Heimberg H, Flamez D, et al. (1996). Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes, 45:257–61
   PubMed Web of Science ®Google Scholar
• Mortensen K, Christensen LL, Holst JJ, Orskov C. (2003). GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept, 114:189–96
   PubMed Web of Science ®Google Scholar
• Muscelli E, Mari A, Casolaro A, et al. (2008). Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes, 57:1340–8
   PubMed Web of Science ®Google Scholar
• Natalicchio A, De Stefano F, Orlando MR, et al. (2010). Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells. Endocrinology, 151:2019–29
   PubMed Web of Science ®Google Scholar
• Natalicchio A, Biondi P, Marrano N, et al. (2013). Prolonged exposure of pancreatic beta-cells to palmitate results in reduced incretin action and signaling via CREB and Akt. Accepted as OP at 73rd Scientific Session of American Diabetes Association (ADA) – Chicago
   Google Scholar
• Nauck MA. (2011). Incretin-based therapies for type 2 diabetes mellitus, properties, functions, and clinical implications Am J Med, 124:S3–18
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, et al. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol, 273:E981–8
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. (2002). Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab, 87:1239–46
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Orskov C, et al. (1993). Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest, 91:301–7
   PubMed Web of Science ®Google Scholar
• Nicolaus M, Brödl J, Linke R, et al. (2011). Endogenous GLP-1 regulates postprandial glycemia in humans, relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab, 96:229–36
   PubMed Web of Science ®Google Scholar
• Orskov C, Wettergren A, Holst JJ. (1996). Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol, 31:665–70
   PubMed Web of Science ®Google Scholar
• Orskov C, Rabenhøj L, Wettergren A, et al. (1994). Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes, 43:535–9
   PubMed Web of Science ®Google Scholar
• Pan QR, Li WH, Wang H, et al. (2009). Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell. Horm Metab Res, 41:799–804
   PubMed Web of Science ®Google Scholar
• Perry T, Holloway HW, Weerasuriya A, et al. (2007). Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol, 203:293–301
   PubMed Web of Science ®Google Scholar
• Piteau S, Olver A, Kim SJ, et al. (2007). Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun, 362:1007–12
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Beety JM, Morgan LM, et al. (1996). Attenuated GLP-1 secretion in obesity, cause or consequence? Gut, 38:916–19
   PubMed Web of Science ®Google Scholar
• Rask E, Olsson T, Söderberg S, et al. (2001). Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care, 24:1640–5
   PubMed Web of Science ®Google Scholar
• Rüttimann EB, Arnold M, Geary N, Langhans W. (2010). GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav, 100:291–6
   PubMed Web of Science ®Google Scholar
• Ryskjaer J, Deacon CF, Carr RD, et al. (2006). Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake. Eur J Endocrinol, 155:485–93
   PubMed Web of Science ®Google Scholar
• Salehi M, Vahl TP, D’Alessio DA. (2008). Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab, 93:4909–16
   PubMed Web of Science ®Google Scholar
• Saxena R, Hivert MF, Langenberg C, et al. (2010). Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet, 42:142–8
   Google Scholar
• Schirra J, Sturm K, Leicht P, et al. (1998). Exendin (9–39) amide is an antagonist of glucagon-like peptide-1 (7–36) amide in humans. J Clin Invest, 101:1421–30
   PubMed Web of Science ®Google Scholar
• Schirra J, Nicolaus M, Roggel R, et al. (2006). Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antropyloro-duodenal motility in humans. Gut, 55:243–51
   PubMed Web of Science ®Google Scholar
• Simonsson E, Ahren B. (1998). Potentiated beta-cell response to non-glucose stimuli in insulin-resistant C57BL/6J mice. Eur J Pharmacol, 350:243–50
   PubMed Web of Science ®Google Scholar
• Song WJ, Seshadri M, Ashraf U, et al. (2011). Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab, 13:308–19
   PubMed Web of Science ®Google Scholar
• Sparsø T, Grarup N, Andreasen C, et al. (2009). Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia, 52:1308–14
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB, Damholt MB, Madsbad S, et al. (2001). Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab, 86:3717–23
   PubMed Web of Science ®Google Scholar
• Ugleholdt R, Poulsen ML, Holst PJ, et al. (2006). Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem, 281:11050–7
   PubMed Web of Science ®Google Scholar
• Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB. (1996). Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM), evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol, 135:425–32
   PubMed Web of Science ®Google Scholar
• Verdich C, Flint A, Gutzwiller JP, et al. (2001a). A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab, 86:4382–9
   PubMed Web of Science ®Google Scholar
• Verdich C, Toubro S, Buemann B, et al. (2001b). The role of postprandial releases of insulin and incretin hormones in meal-induced satiety – effect of obesity and weight reduction. Int J Obes Relat Metab Disord, 25:1206–14
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Agersø H, Krarup T, Holst JJ. (2003b). Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab, 88:220–4
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Agersø H, Lauritsen T, et al. (2006). The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept, 137:168–72
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Deacon CF, et al. (2001). Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50:609–13
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Madsbad S, Holst JJ. (2002). Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia, 45:1111–19
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Sonne J, et al. (2003a). Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab, 88:2706–13
   PubMed Web of Science ®Google Scholar
• Vollmer K, Gardiwal H, Menge BA, et al. (2009). Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab, 94:1379–85
   PubMed Web of Science ®Google Scholar
• Vollmer K, Holst JJ, Baller B, et al. (2008). Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes, 57:678–87
   PubMed Web of Science ®Google Scholar
• Whalley N, Pritchard L, Smith DM, White A. (2011). Processing of proglucagon to GLP-1 in pancreatic alpha cells: is this a paracrine mechanism enabling GLP-1 to act on beta cells? J Endocrinol, 211:99–106
   PubMed Web of Science ®Google Scholar
• Williams DL, Baskin DG, Schwartz MW. (2009). Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology, 150:1680–7
   PubMed Web of Science ®Google Scholar
• Xie D, Zhong Q, Ding KH, et al. (2007). Glucose-dependent insulinotropic peptide overexpressing transgenic mice have increased bone mass. Bone, 40:1352–60
   PubMed Web of Science ®Google Scholar
• Yasuda N, Inoue T, Nagakura T, et al. (2002). Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun, 298:779–84
   PubMed Web of Science ®Google Scholar
• Yip RG, Wolfe MM. (2000). GIP biology and fat metabolism. Life Sci, 66:91–103
   PubMed Web of Science ®Google Scholar